Market closedADR
Barinthus Biotherapeutics/$BRNS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Barinthus Biotherapeutics
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
Ticker
$BRNS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
130
Website
BRNS Metrics
BasicAdvanced
$45M
Market cap
-
P/E ratio
-$1.49
EPS
-0.72
Beta
-
Dividend rate
Price and volume
Market cap
$45M
Beta
-0.72
52-week high
$4.16
52-week low
$0.80
Average daily volume
71K
Financial strength
Current ratio
8.934
Quick ratio
8.391
Long term debt to equity
6.699
Total debt to equity
7.945
Interest coverage (TTM)
-1,299.54%
Management effectiveness
Return on assets (TTM)
-18.65%
Return on equity (TTM)
-32.60%
Valuation
Price to revenue (TTM)
2.889
Price to book
0.28
Price to tangible book (TTM)
0.35
Price to free cash flow (TTM)
-0.696
Growth
Revenue change (TTM)
106.21%
Earnings per share change (TTM)
-26.59%
3-year revenue growth (CAGR)
188.56%
3-year earnings per share growth (CAGR)
-15.13%
What the Analysts think about BRNS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Barinthus Biotherapeutics stock.
BRNS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BRNS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BRNS News
AllArticlesVideos
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
GlobeNewsWire·4 weeks ago
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
GlobeNewsWire·1 month ago
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Barinthus Biotherapeutics stock?
Barinthus Biotherapeutics (BRNS) has a market cap of $45M as of December 22, 2024.
What is the P/E ratio for Barinthus Biotherapeutics stock?
The price to earnings (P/E) ratio for Barinthus Biotherapeutics (BRNS) stock is 0 as of December 22, 2024.
Does Barinthus Biotherapeutics stock pay dividends?
No, Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next Barinthus Biotherapeutics dividend payment date?
Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders.
What is the beta indicator for Barinthus Biotherapeutics?
Barinthus Biotherapeutics (BRNS) has a beta rating of -0.72. This means that it has an inverse relation to market volatility.